For brain infection, radiological examinations including plain skull x-rays, brain CT, and MR scans are used. A rapid antibody detection kit, dot-immunogold filtration assay (DIGFA), was developed for P. Wertermani in China in 2005.Misdiagnosis is a serious issue in paragonimiasis. It is commonly misdiagnosed as tuberculosis because it presents similar symptoms. In China, there were between 69 and 89% of misdiagnostic cases in 10 ten years, from 2009 to 2019. It is also frequently misidentified as malignancy or chronic obstructive pulmonary disease. Treatment
The drug of choice to treat paragonimiasis is praziquantel, although bithionol may also be used. Triclabendazole is useful in P. uterobilateralis, P. mexicanus, and P. skrjabini infections but not in P. westermani infection. See also
Drunken shrimp
Eating live seafood
Odori ebi

References


== External links ==
It was later found that scopolamine impairment in learning was caused by an increase in benzodiazepine/GABA activity (and that benzodiazepines were not associated with the cholinergic system). In tests of various benzodiazepine compounds, chlordiazepoxide was found to cause the most profound reduction in the turnover of 5HT (serotonin) in rats. Serotonin is closely involved in regulating mood and may be one of the causes of feelings of depression in rats using chlordiazepoxide or other benzodiazepines. In September 2020, the U.S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class. Tolerance and dependence
Tolerance
Chronic use of benzodiazepines, such as chlordiazepoxide, leads to the development of tolerance, with a decrease in number of benzodiazepine binding sites in mouse forebrain. The Committee of Review of Medicines, who carried out an extensive review of benzodiazepines including chlordiazepoxide, found—and were in agreement with the Institute of Medicine (USA) and the conclusions of a study carried out by the White House Office of Drug Policy and the National Institute on Drug Abuse (USA)—that there was little evidence that long-term use of benzodiazepines were beneficial in the treatment of insomnia due to the development of tolerance.